Since major biotechnology player Amgen (NASDAQ: AMGN) makes this cut, should we revalue the company in light of the new regulations? Questions about the long-term impact of the Inflation Reduction Act -- whether the law will truly make medicine more affordable for the patients who need it most or squash innovation as pharmaceuticals claim -- are up for debate. Potential biosimilar blockbuster Amjevita for rheumatoid arthritis is finally nearing its January launch after waiting since its Food & Drug Administration approval in 2016 per a legal settlement reached over AbbVie's Humira.